Vigneri, P., & Müller, M. C. (2017). High BCR-ABL/GUS-IS levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib. Clinical cancer research, 23(23), . https://doi.org/10.1158/1078-0432.CCR-17-0962
Chicago-Zitierstil (17. Ausg.)Vigneri, Paolo, und Martin Christian Müller. "High BCR-ABL/GUS-IS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-dose Imatinib." Clinical Cancer Research 23, no. 23 (2017). https://doi.org/10.1158/1078-0432.CCR-17-0962.
MLA-Zitierstil (9. Ausg.)Vigneri, Paolo, und Martin Christian Müller. "High BCR-ABL/GUS-IS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-dose Imatinib." Clinical Cancer Research, vol. 23, no. 23, 2017, https://doi.org/10.1158/1078-0432.CCR-17-0962.